- An observational study of long-term safety concludes that among systemic medications for psoriasis, ustekinumab is associated with reduced incidence of adverse events (AEs), whereas infliximab and cyclosporine are associated with increased incidence of serious AEs.
Why this matters
- Several treatment options for psoriasis have become available in recent years, necessitating comparative safety studies.
- Ustekinumab was associated with reduced incidence of AEs (incidence rate ratio [IRR], 0.7; P<.001 whereas cyclosporine was associated with increased incidence of aes>
- Infliximab (IRR, 5.2; P<.001 and cyclosporine p were associated with increased incidence of serious aes.>
- Infliximab (IRR, 12.9; P<.001 adalimumab and cyclosporine were associated with increased incidence of malignant neoplasms.>
- 2845 patients with moderate to severe psoriasis receiving systemic treatment from the Biobadaderm Registry were included.
- Funding: Spanish Medicines and Health Products Agency; Abbot/AbbVie; Pfizer; MSD; Novartis; Lilly; Janssen; Almirall.
- Observational study design.